Longevity biotech market seen topping $31 billion by 2030

The longevity biotechnology market is forecast to exceed $31 billion by 2030, driven by aging populations, preventive care demand and growth in regenerative medicine. North America is expected to lead the market, while preventive health programs and biological age testing emerge as key revenue pools.

Why it matters: - Longevity biotech is moving from a niche research area into a larger healthcare market tied to aging, prevention and precision medicine. - The market’s growth could shape investment, clinical development and consumer health services focused on extending healthspan, not just lifespan. - The forecast highlights where demand is building fastest, including preventive programs, biological age testing and regenerative therapies.

What happened: - The Business Research Company published its Longevity BioTech Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report projects the longevity biotech market will exceed $31 billion in 2030. - The broader Longevity and Anti-senescence Therapy market is projected to reach nearly $40 billion by 2030. - The sector is forecast to grow at an 8% compound annual growth rate through 2030. - North America is projected to be the largest regional market, reaching $12 billion by 2030. - The United States is projected to be the largest single-country market, reaching $11 billion by 2030.

The details: - Longevity biotech is expected to account for about 78% of the broader Longevity and Anti-senescence Therapy market by 2030. - The sector is expected to represent close to 0.3% of the total Healthcare Services market, which is projected to reach $11,335 billion by 2030. - North America’s market value is projected to rise from $8 billion in 2025 to $12 billion in 2030, a 9% CAGR. - The U.S. market is projected to rise from $7 billion in 2025 to $11 billion in 2030, also at a 9% CAGR. - The report points to venture capital funding, clinical development of senolytic and cellular regeneration treatments, and partnerships among biotech firms, academic institutions and healthcare organizations as growth drivers in North America. - The U.S. market is being supported by private investment in age-related disease therapeutics, more clinical trials, AI-assisted drug discovery, more longevity clinics and commercialization of precision health services. - Strong intellectual property portfolios in regenerative biotech are also supporting U.S. growth. - Three major demand drivers are aging populations, consumer demand for therapies that support mobility, immunity and cognition, and growing interest in preventive healthcare. - The report estimates aging-population demand could contribute about 1.5% annual growth. - Demand from older consumers seeking therapies and tools to slow decline could contribute about 1.0% annual growth. - Preventive healthcare interest could add about 0.8% annual growth each year. - Longevity consultation, biological age testing and preventive health programs are expected to contribute more than $11 billion in market value by 2030. - Biological age testing alone is projected to grow by $5 billion. - Preventive health programs are projected to be the largest service segment in 2030, representing 41% of the market or around $13 billion. - The report says that segment’s growth is being supported by wearables, evidence-based nutrition, multi-omics-driven prevention and digital wellness platforms. - The industry is segmented by approach, including senolytics, gene therapies, regenerative medicine, metabolic modulators and mitochondrial therapies. - The technology stack includes gene editing, artificial intelligence and machine learning, stem cell therapies, multi-omics platforms and advanced drug screening tools. - Applications include healthcare, biotech, pharmaceuticals, wellness and aging populations. - End users include clinics, hospitals, research institutes and direct-to-consumer channels. - Small interfering RNA-based cellular reprogramming therapies are gaining attention for their potential to restore cellular function and counter age-related decline. - In December 2025, Junevity advanced JUN_01, a candidate siRNA therapy targeting age-related transcriptional dysregulation. - The company says JUN_01 is designed to improve insulin sensitivity, reduce blood glucose and promote durable, fat-selective weight loss in metabolic disorders. - The market remains highly fragmented. - In 2025, the top 10 companies held just 0.3% of total revenue combined. - Regulatory demands, long clinical trials and the need for scientific validation and safety create moderate barriers to entry. - Leading companies are using cellular reprogramming, gene editing, regenerative medicine, anti-aging drug discovery and artificial intelligence to compete. - Altos Labs ranked first globally in sales in 2025 with a 0.05% market share. - The report lists other major players including Calico Life Sciences, Retro Biosciences, Insilico Medicine, NewLimit, Juvenescence, Unity Biotechnology, Cambrian BioPharma, Life Biosciences and Rubedo Life Sciences. - Emerging companies named in the report include Cleara Biotech, Halia Therapeutics, Centenara Labs, Junevity, Rejuvenate Bio and Liv Longevity Labs. - Suppliers cited include Thermo Fisher Scientific, Merck KGaA, Sartorius, Lonza and Danaher. - Wholesalers and distributors cited include McKesson, Cardinal Health, Cencora, Owens & Minor and Medline Industries.

Between the lines: - The market forecast suggests longevity biotech is becoming a broader platform for preventive and precision healthcare, not just anti-aging science. - The small revenue shares among the biggest players show a field that is still early and highly dispersed. - AI, biological age testing and personalized prevention appear to be the clearest commercial bridges between research and revenue.

What's next: - More capital, clinical trials and partnerships are likely as companies race to validate therapies and diagnostics. - Biological age testing and preventive health programs may keep expanding as consumer demand for measurable health optimization rises. - Junevity’s siRNA program is one example of the pipeline activity that could influence the next phase of the market.

The bottom line: - Longevity biotech is projected to grow steadily through 2030, with North America leading and preventive care emerging as the biggest commercial wedge.